Of two trials that compared surgery with watchful waiting,3,4 only the Scandinavian Prostate Cancer Group-4 trial (SPCG-4), conducted in the pre-PSA (Prostate Specific Antigen) era, evaluated costs. The gene discussed is KLK3; the disease is prostate carcinoma.